Antineoplastic Agents, Immunological
DBCAT004966Pharmacologic class
Monoclonal antibodies that inhibit or prevent the proliferation of NEOPLASMS. A DrugBank category of 76 drugs. 47 of them are approved.
- Also known as
- Monoclonal antibodies - antineoplastics
- Drugs
- Abagovomab
- Abatacept
- Adagrasib
- Alemtuzumab
- Amivantamab
- Atezolizumab
- Avelumab
- Axicabtagene ciloleucel
- Bavituximab
- Belatacept
- Bemarituzumab
- Bevacizumab
- BI-836826
- Bivatuzumab mertansine
- Brentuximab vedotin
- Brexucabtagene autoleucel
- Cantuzumab mertansine
- Cemiplimab
- Cetuximab
- Conatumumab
- CT-011
- Dacetuzumab
- Daraxonrasib
- Datopotamab deruxtecan
- Durvalumab
What you can answer from here — as of May 21, 2021
Which targets do Antineoplastic Agents, Immunological share, and which companies have late-stage candidates in this class?
Create a free account or log in to explore the full data card.
Create Account